Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report [4]

Value in Health

Volumn 21, Issue 2, 2018, Pages 140-145

  Danzon, Patricia M ^a   Drummond, Michael F ^b   Towse, Adrian ^c   Pauly, Mark V ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF YORK   (United Kingdom)

^c Office of Health Economics   (United Kingdom)

Author keywords

budgets; cost effectiveness; opportunity cost; thresholds

Indexed keywords

ARTICLE; BUDGET; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MEDICAID; MEDICARE; PRIORITY JOURNAL; PRIVATE SECTOR; TAX; UNCERTAINTY; UNITED STATES; ADVISORY COMMITTEE; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; HEALTH CARE DELIVERY; HEALTH INSURANCE; INSURANCE; OUTCOME ASSESSMENT; PROCEDURES; QUALITY ADJUSTED LIFE YEAR;

ADVISORY COMMITTEES; BUDGETS; COST-BENEFIT ANALYSIS; DECISION MAKING; DELIVERY OF HEALTH CARE; HEALTH EXPENDITURES; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE CARRIERS; INSURANCE, HEALTH; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 85042313236     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2017.12.008     Document Type: Article

References (14)

1. Neumann, P.J., Sanders, G.D., Russell, L.B., et al. Cost-Effectiveness in Health and Medicine. 2017, Oxford University Press, New York, NY.
2. Phelps, C.E., Lakdawalla, D.N., Basu, A., Drummond, M.F., Towse, A., Danzon, P.M., Approaches to aggregation and decision making—a health economics approach: an ISPOR Special Task Force report [5]. Value Health 21 (2018), 146–154.
3. Garrison, L.P., Pauly, M.V., Willke, R.J., Neumann, P.J., An overview of value, perspective, and decision context—a health economics approach: an ISPOR Special Task Force report [2]. Value Health 21 (2018), 124–130.
4. McCabe, C.K., Claxton, K., Culyer, A.J., The NICE cost-effectiveness threshold: what it is and what it means. Pharmacoeconomics 26 (2016), 733–744.
5. Tan-Torres Edejer, T., Baltussen, R.M., Adam, T., et al. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. 2003, World Health Organization, Geneva, Switzerland.
6. Lakdawalla, D.N., Doshi, J.A., Garrison, L.P., Phelps, C.E., Basu, A., Danzon, P.M., Defining elements of value in health care—a health economics approach: an ISPOR Special Task Force report [3]. Value Health 21 (2018), 131–139.
7. National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments. Available from: https://www.nice.org.uk/guidance/gid-tag387/resources/appraising-life-extending-end-of-life-treatments-paper2. [Accessed April 29, 2017].
8. Scottish Medicines Consortium. SMC modifiers used in appraising new medicines. Available from: http://www.scottishmedicines.org.uk/About_SMC/Policy_statements/SMC_Modifiers_used_in_Appraising_New_Medicines. [Accessed January 3, 2018].
9. Eckermann, S., Willan, A.R., Expected value of information and decision making in HTA. Health Econ 16 (2007), 195–209.
10. Hines, J.R., Three sides of the Harberger triangles. NBER Working Paper 6852, 1998, National Bureau of Economic Research, Cambridge, MA.
11. Claxton, K., Martin, S., Soares, M., et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 19 (2015), 1–503.
12. Barnsley, P., Towse, A., Karlsberg Schaffer, S., Sussex, J., Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold. 2013, Office of Health Economics, London.
13. Barnsley, P., Cubi-Molla, P., Fischer, A., Towse, A., Uncertainty and Risk in HTA Decision Making. OHE Research Report, 2016, Office of Health Economics, London.
14. Baicker, K., Skinner, J., Health care spending growth and the future of US tax rates. 2011, NBER Retirement Research Center Paper NB 11-14, National Bureau of Economic Research, Cambridge, MA.